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the outcomes of these patients treated with external beam 
radiotherapy (EBRT) and interstitial brachytherapy. 
 
Material and Methods: Ninety patients were accrued 
between October 2008 and May 2014. All the patients 
underwent prior hysterectomy and were diagnosed to have 
recurrent vault cancers with squamous cell carcinomas. Only 
patients with minimum gap of 6 months between the 
hysterectomy and recurrence were accrued in the study. All 
underwent EBRT of 50Gy (2Gy/fraction) to pelvis and 
simultaneous boost to the pelvic nodes of (10 Gy/5 fraction) 
if present, using Intensity Modulated Radiotherapy with 
concurrent chemotherapy of weekly cisplatin (40mg/mt2) 
followed by HDR Interstitial brachytherapy boost of 20Gy 
(4Gy/fraction b.i.d).  
 
Results: Eighty (88%) patients were post simple hysterectomy 
and 20(22%) had Wertheim’s hysterectomy, 16 (18%) had 
pelvic nodes and 46(51%) had parametrial extension upto the 
pelvic side walls. All the patients completed EBRT and 
concurrent chemotherapy and 28 (31%) patients had gross 
residual disease at the time of interstitial brachytherapy. 
Post brachytherapy 5 patients continued to have persistent 
disease, 6 had local relapse, 2 had local + distant relapse and 
9 patients had only distant relapse. At the median follow up 
of 42 months for the surviving patients the local control rate 
was 86% and the 5-year actuarial disease-free survival (DFS) 
and overall survival (OAS) was 75%, 71%. In univariate analysis 
OAS was influenced by tumor involving the pelvic side wall 
(55% vs 84% p=0.004) and large pelvic nodes >1cm (44% 
VS.73% P=0.01) at presentation and partial vs. complete 
tumor response to EBRT at the time of brachytherapy (40% 
vs. 83% p=0.001). On multivariate analysis pelvic nodes at 
presentation and the tumor response to EBRT were significant 
factors affecting DFS and OAS. Other factors such as age, 
disease volume, and vaginal extension did not impact the 
survivals. Grade III/IV rectal toxicity was seen in 5 (5%) 
patients, bladder toxicity in 3 (3%) patients, whereas none of 
the patients developed Grade III small bowel toxicity.  
 
Conclusion: Using EBRT with concurrent chemotherapy and 
interstitial brachytherapy a majority of the recurrences can 
be salvaged. An excellent local control and survival is 
achievable using this technique and 28 (31%) patients had 
gross residual disease at the time of interstitial 
brachytherapy.  
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Purpose or Objective: Introducing a fast technique to 
estimate bladder dose due to interfractional variations. 
 
Material and Methods: 30 cervical cancer patients treated 
with HDR intracavitary brachytherapy were selected. After 
applicator insertion all cases pelvic CT scans were performed 
twice; pre- and post-treatment (15-30 min after dose 
delivery), with applicator in situ and identical bladder filling 
protocol. A 3D treatment planning software (TPS) 
(Flexiplan®, version 2.6, Isodose control, the Netherlands) 
was used. Applicator (Rotterdam tandem-ovoid) 
reconstruction and organs contouring were done by the same 
physicist and physician on both image series. Planning was 
performed on the pre-treatment CT. Fractional prescription 
dose was calculated for each patient based on the EQD2 and 
defined planning aims: 80-90 Gy for D90 of the high-risk 
clinical target volume and D2cm³ of bladder, rectum, and 
sigmoid less than 85, 75, and 75, respectively. DVH 
parameters (D2cm³, D0.1cm³, D10, D30, and D50) were 
recorded after each planning. 192Ir dwell times were copied 
manually to the post-treatment CT in the TPS. The 
recalculations of the DVH parameters showed the 
interfractional OAR dose variations. Images and structures of 
each pre- and post-treatment plan were exported in DICOM 
format to an in-house MATLAB written code. An artificial 
neural network (ANN) based on the 'back-propagation 
algorithm' was developed to predict the OARs dose variations. 
ANN input data was based on the changes of OAR wall 
distance-to-dwell positions along the applicators, that were 
extracted from two images series of each case. 25 cases were 
randomly selected as the training and model validation set 
(20 cases for training and 5 for validation), and the last 5 one 
for the resulted ANN model testing. Testing was performed 
by comparing the interfractional dose variations obtained 
from TPS calculated DVH and that obtained from ANN-based 
computing. The performance of the ANN was analyzed by 
root mean square error (RMSE). 
 
Results: RMSE of the designed ANN was 0.28. RMSE of the 
testing cases was 0.72. TPS-based interfractional variations 
for D2cm³ were -2.9 % ± 18.7 %. As an example of the model 
performance, relative differences of TPS-calculated and ANN-
based interfractional variations for D2cm³ of the training + 
validation cases (just the first 25 ones) are presented 
schematically in the Figure 1. It can be seen that these 
relative differences are almost less than 3%. 
 
 
Conclusion: An ANN-based model was introduced which can 
give a fast prediction of bladder interfractional dose 
variations during cervical cancer intracavitary brachytherapy 
independent from TPS based dose calculations. This can serve 
as a basis for online verification tools in brachytherapy dose 
delivery. 
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Purpose or Objective: Last decade has witnessed a 
revolution in breast conservation (BCS) in India as a 
consequence of sustained awareness campaigns and 
detection of early cases. But success of BCS demands not only 
local control but cosmetic excellence as well. Radiotherapy 
plays a major role in this treatment and selected high risk 
cases require boost also . This retrospective analysis aims to 
